Facilitating Antibacterial Drug Development in a Time of Great Need.

The continued development of new antibacterial drugs is critical to meet patient and public health needs. In this editorial, authors from the US Food and Drug Administration and European Medicines Agency reflect on the role of public-private partnerships and the development of clinical trials networks as agents to guide and perform quality studies of antibacterial drugs.

[1]  V. Fowler,et al.  Improving Conduct and Feasibility of Clinical Trials to Evaluate Antibacterial Drugs to Treat Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia: Recommendations of the Clinical Trials Transformation Initiative Antibacterial Drug Development Project Team. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  H. Goossens,et al.  Efficient Delivery of Investigational Antibacterial Agents via Sustainable Clinical Trial Networks , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  Y. Schlesinger Editorial Commentary: Amniocentesis for Detection of Congenital Cytomegalovirus Infection: What Is the Point? , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[4]  S. Burns,et al.  Transmission of Hepatitis B Core Antibody and Galactomannan Enzyme Immunoassay Positivity via Immunoglobulin Products: A Comprehensive Analysis. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  Ronald N. Jones,et al.  10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  Amber Jessup,et al.  ANALYTICAL FRAMEWORK FOR EXAMINING THE VALUE OF ANTIBACTERIAL PRODUCTS , 2014 .